2001
Immunological Detection of a Novel Advanced Glycation End-Product
Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z. Immunological Detection of a Novel Advanced Glycation End-Product. Molecular Medicine 2001, 7: 783-791. PMID: 11788793, PMCID: PMC1950006, DOI: 10.1007/bf03401969.Peer-Reviewed Original Research
1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplicationsInhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol
Al-Abed Y, Mitsuhashi T, Li H, Lawson J, FitzGerald G, Founds H, Donnelly T, Cerami A, Ulrich P, Bucala R. Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 2385-2390. PMID: 10051651, PMCID: PMC26793, DOI: 10.1073/pnas.96.5.2385.Peer-Reviewed Original Research
1998
Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis
Chou S, Wang H, Taniguchi A, Bucala R. Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis. Molecular Medicine 1998, 4: 324-332. PMID: 9642682, PMCID: PMC2230387, DOI: 10.1007/bf03401739.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisSporadic amyotrophic lateral sclerosisNeurofilament proteinNeuronal inclusionsLateral sclerosisAGE formationNitric oxide-mediated responsesAnti-AGE antibodyAdvanced glycation endproductsMethodsParaffin sectionsMotor neuronsConclusionsThese dataAdvanced glycationGlycation endproductsNeuronal toxicityNitric oxideSpecific antibodiesProtein nitrationConcomitant inductionSclerosisSuperoxide dismutasePatientsAntibodiesPotent oxidantFree radicals
1997
Tobacco smoke is a source of toxic reactive glycation products
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsTobacco smokeGlycation productsAGE formationSerum AGE levelsIncidence of atherosclerosisPlasma of patientsGlycation end productsRenal insufficiencyCerebrovascular diseaseCigarette smokersHuman smokersHigh prevalenceHigh riskSmokersNonsmokersGlycotoxinsPatientsSpecific fluorescenceSerum proteinsDiseaseCuring of tobaccoAqueous extractSmokeTobacco
1996
Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis
Bucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrology Dialysis Transplantation 1996, 11: 17-19. PMID: 9044301, DOI: 10.1093/ndt/11.supp5.17.Peer-Reviewed Original ResearchConceptsLDL receptorAGE modificationApolipoprotein BAdvanced glycosylationHuman fibroblast LDL receptorsAGE-modified formAGE-specific antibodiesRegion of apoBNon-diabetic individualsFibroblast LDL receptorLDL receptor binding siteRenal insufficiencyDiabetes mellitusDiabetic patientsElevated LDLAGE-LDLLipoprotein clearanceReceptor binding sitesHuman LDL receptorGeneral populationPlasma clearance kineticsTransgenic miceLDLAGE formationClearance kinetics
1995
Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *
Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *. Journal Of Biological Chemistry 1995, 270: 10828-10832. PMID: 7738020, DOI: 10.1074/jbc.270.18.10828.Peer-Reviewed Original ResearchConceptsLow-density lipoproteinAGE-modified formAdvanced glycosylation end productsLDL receptorApolipoprotein BHuman fibroblast LDL receptorsAGE-specific antibodiesApolipoprotein B modificationDiabetic vascular diseaseLow-density lipoprotein receptorGlycosylation end productsDensity lipoprotein receptorFibroblast LDL receptorMajor siteAGE immunoreactivityRenal insufficiencyGlucose-derived Amadori productsVascular diseasePlasma clearance kineticsDensity lipoproteinLipoprotein receptorAGE formationClearance kineticsAGE modificationPredominant site